Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23342) 23342
Conference Proceeding (172) 172
Magazine Article (99) 99
Book / eBook (19) 19
Reference (9) 9
Publication (8) 8
Web Resource (7) 7
Streaming Video (5) 5
Dissertation (1) 1
Government Document (1) 1
Newsletter (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
biological and medical sciences (15915) 15915
medical sciences (15852) 15852
humans (15718) 15718
science & technology (15336) 15336
life sciences & biomedicine (15186) 15186
pharmacology. drug treatments (14272) 14272
neuropharmacology (13742) 13742
anticonvulsants. antiepileptics. antiparkinson agents (13497) 13497
male (12600) 12600
neurosciences & neurology (10508) 10508
female (9502) 9502
clinical neurology (8168) 8168
animals (7320) 7320
parkinson disease - drug therapy (6810) 6810
neurology (6517) 6517
antiparkinson agents - therapeutic use (6350) 6350
middle aged (6314) 6314
aged (5237) 5237
adult (4921) 4921
parkinson's disease (4733) 4733
pharmacology & pharmacy (4143) 4143
neurosciences (4094) 4094
nervous system (3929) 3929
rats (3902) 3902
levodopa - therapeutic use (3422) 3422
headache. facial pains. syncopes. epilepsia. intracranial hypertension. brain oedema. cerebral palsy (3317) 3317
antiparkinson agents - adverse effects (3177) 3177
epilepsy (2980) 2980
dose-response relationship, drug (2398) 2398
anticonvulsants - therapeutic use (2292) 2292
parkinson disease - physiopathology (2145) 2145
adolescent (2092) 2092
treatment outcome (2067) 2067
epilepsy - drug therapy (2017) 2017
antiparkinson agents - administration & dosage (1988) 1988
antiparkinson agents - pharmacology (1988) 1988
anticonvulsants - pharmacology (1929) 1929
mice (1893) 1893
levodopa - adverse effects (1877) 1877
abridged index medicus (1855) 1855
drug therapy, combination (1646) 1646
degenerative and inherited degenerative diseases of the nervous system. leukodystrophies. prion diseases (1639) 1639
child (1563) 1563
time factors (1494) 1494
levodopa - administration & dosage (1390) 1390
levodopa (1389) 1389
seizures (1362) 1362
disease models, animal (1356) 1356
analysis (1311) 1311
parkinson disease - complications (1296) 1296
anticonvulsants (1290) 1290
psychiatry (1205) 1205
rats, sprague-dawley (1203) 1203
aged, 80 and over (1165) 1165
dopamine (1128) 1128
double-blind method (1083) 1083
drug interactions (1064) 1064
rats, wistar (984) 984
child, preschool (948) 948
severity of illness index (920) 920
anticonvulsants - adverse effects (917) 917
parkinson’s disease (905) 905
follow-up studies (896) 896
motor activity - drug effects (891) 891
drug administration schedule (890) 890
parkinson disease - therapy (890) 890
levodopa - pharmacology (886) 886
electroencephalography (862) 862
dopamine - metabolism (842) 842
parkinsons disease (829) 829
retrospective studies (819) 819
drug therapy (814) 814
dopa (804) 804
anticonvulsants - pharmacokinetics (801) 801
brain - drug effects (786) 786
rats, inbred strains (782) 782
brain - metabolism (772) 772
parkinson disease - diagnosis (763) 763
parkinson disease - psychology (752) 752
anticonvulsants - administration & dosage (736) 736
dopamine agonists - therapeutic use (725) 725
risk factors (688) 688
seizures - drug therapy (679) 679
parkinson disease - metabolism (665) 665
magnetic resonance imaging (664) 664
seizures - chemically induced (659) 659
carbamazepine (653) 653
in vitro techniques (652) 652
movement disorders (639) 639
behavior, animal - drug effects (635) 635
medicine & public health (633) 633
epilepsy - physiopathology (618) 618
analysis of variance (616) 616
clinical trials as topic (614) 614
age factors (610) 610
drug combinations (606) 606
parkinsonian disorders - drug therapy (606) 606
care and treatment (600) 600
prospective studies (600) 600
administration, oral (590) 590
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (14) 14
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Baycrest Hospital - Stacks (1) 1
Baycrest Hospital - Wellness Library (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22620) 22620
German (292) 292
Japanese (240) 240
French (224) 224
Spanish (209) 209
Russian (157) 157
Polish (50) 50
Portuguese (49) 49
Dutch (37) 37
Hungarian (31) 31
Italian (29) 29
Danish (24) 24
Chinese (22) 22
Norwegian (21) 21
Swedish (18) 18
Finnish (11) 11
Hebrew (8) 8
Romanian (7) 7
Czech (6) 6
Serbian (4) 4
Ukrainian (2) 2
Bosnian (1) 1
Croatian (1) 1
Icelandic (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Exosomes as drug delivery vehicles for Parkinson's disease therapy
by Haney, Matthew J and Klyachko, Natalia L and Zhao, Yuling and Gupta, Richa and Plotnikova, Evgeniya G and He, Zhijian and Patel, Tejash and Piroyan, Aleksandr and Sokolsky, Marina and Kabanov, Alexander V and Batrakova, Elena V
Journal of controlled release, ISSN 0168-3659, 06/2015, Volume 207, pp. 18 - 30
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles | Index Medicus | blood-brain barrier | neuroinflammation | exosomes | catalase | oxidative stress | Parkinson’s disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Hybrid molecules incorporating natural products: Applications in cancer therapy, neurodegenerative disorders and beyond
by Decker, M
Current medicinal chemistry, ISSN 0929-8673, 04/2011, Volume 18, Issue 10, pp. 1464 - 1475
Antioxidants | Antitumor agents | Parkinson's disease | Natural products | Alzheimer's disease | Neurodegenerative disorders | Cancer | Hybrid molecules | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Antioxidants - chemistry | Antineoplastic Agents - chemical synthesis | Humans | Alzheimer Disease - drug therapy | Antimalarials - therapeutic use | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Antioxidants - chemical synthesis | Antineoplastic Agents - chemistry | Neurodegenerative Diseases - drug therapy | Neoplasms - drug therapy | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Antimalarials - chemistry | Drug Design | Pharmaceutical Preparations - chemistry | Biological Products - administration & dosage | Pharmaceutical Preparations - administration & dosage | Antimalarials - chemical synthesis
Journal Article
Details down arrow
3. Full Text Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action
by Zirak, Nahid and Shafiee, Mojtaba and Soltani, Ghasem and Mirzaei, Mohammad and Sahebkar, Amirhossein
Journal of cellular physiology, ISSN 0021-9541, 06/2019, Volume 234, Issue 6, pp. 8496 - 8508
Hypericum perforatum | anxiety | neurodegenerative diseases | depression | psychiatric disorders | Physiology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Antiparkinson Agents - isolation & purification | Hypericum - adverse effects | Humans | Nootropic Agents - isolation & purification | Nootropic Agents - therapeutic use | Plant Extracts - isolation & purification | Anti-Anxiety Agents - isolation & purification | Nootropic Agents - adverse effects | Antiparkinson Agents - adverse effects | Antidepressive Agents - isolation & purification | Antidepressive Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Animals | Anti-Anxiety Agents - adverse effects | Anti-Anxiety Agents - therapeutic use | Antidepressive Agents - adverse effects | Plant Extracts - therapeutic use | Hypericum - chemistry | Plant Extracts - adverse effects | Nervous system | Care and treatment | Degeneration | Health aspects | Depression, Mental | Antidepressants, Tricyclic | Medical research | Effectiveness | Mental disorders | Neurodegenerative diseases | Serotonin | Mental health | Disorders | Clinical trials | Serotonin uptake inhibitors | Mental depression | Quality of life | Herbal medicine | Side effects | Properties (attributes) | Hypericin | Antidepressants | Tricyclic antidepressants | In vivo methods and tests | Anxiety | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Antiepileptic drug combinations—Have newer agents altered clinical outcomes?
by Stephen, Linda J and Forsyth, Murray and Kelly, Kevin and Brodie, Martin J
Epilepsy research, ISSN 0920-1211, 2011, Volume 98, Issue 2, pp. 194 - 198
Neurology | Antiepileptic drug | Polytherapy | Seizure | Epilepsy | Combination | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Pharmacology. Drug treatments | Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy | Biological and medical sciences | Anticonvulsants. Antiepileptics. Antiparkinson agents | Medical sciences | Neuropharmacology | Nervous system (semeiology, syndromes) | Humans | Middle Aged | Anticonvulsants - therapeutic use | Male | Treatment Outcome | Young Adult | Drug Therapy, Combination - methods | Drug Interactions | Adolescent | Aged, 80 and over | Adult | Drug Therapy, Combination - statistics & numerical data | Epilepsy - drug therapy | Female | Aged | Retrospective Studies | Drug Combinations | Anticonvulsants | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text 2-Azetidinone – A new profile of various pharmacological activities
by Mehta, Parul D and Sengar, N.P.S and Pathak, A.K
European journal of medicinal chemistry, ISSN 0223-5234, 2010, Volume 45, Issue 12, pp. 5541 - 5560
2-Azetidinone | β-Lactam | Biological activity | Four membered heterocyclic ring | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Biological and medical sciences | Miscellaneous | Medical sciences | Pharmacology. Drug treatments | Antifungal Agents - pharmacology | Animals | Antiparkinson Agents - pharmacology | Anti-Infective Agents - chemistry | Anti-Infective Agents - pharmacology | Humans | Antiparkinson Agents - chemistry | Antifungal Agents - chemistry | Hypoglycemic Agents - chemistry | Azetidines - pharmacology | Azetidines - chemistry | Hypoglycemic Agents - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text POMA analyses as new efficient bioinformatics’ platform to predict and optimise bioactivity of synthesized 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues
by Ahsan, Mohamed Jawed and Govindasamy, Jeyabalan and Khalilullah, Habibullah and Mohan, Govind and Stables, James P and Pannecouque, Christophe and Clercq, Eric De
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 12/2012, Volume 22, Issue 23, pp. 7029 - 7035
Petra/Osiris/Molinspiration/ALOGPS 2.1 program | Anti-HIV | Antifungal | Tautomerism | Anticonvulsant | Antibacterial | Pyrazolines | Antiviral agents | Pharmacology. Drug treatments | Antifungal agents | Biological and medical sciences | Anticonvulsants. Antiepileptics. Antiparkinson agents | Medical sciences | Neuropharmacology | Antibacterial agents | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anti-HIV Agents - pharmacology | Anti-HIV Agents - toxicity | Amides - chemical synthesis | Escherichia coli - drug effects | Humans | Motor Activity - drug effects | Antifungal Agents - chemical synthesis | Antifungal Agents - chemistry | Anticonvulsants - pharmacology | Microbial Sensitivity Tests | Pyrazoles - chemistry | Candida albicans - drug effects | Anti-Bacterial Agents - chemistry | Antifungal Agents - pharmacology | Cell Line | Cell Survival - drug effects | Thioamides - chemistry | Anticonvulsants - chemical synthesis | HIV-1 - drug effects | Computational Biology | Pseudomonas aeruginosa - drug effects | Anti-Bacterial Agents - chemical synthesis | HIV-2 - drug effects | Anti-HIV Agents - chemistry | Animals | Anticonvulsants - chemistry | Amides - chemistry | Thioamides - chemical synthesis | Anti-Bacterial Agents - pharmacology | Aspergillus niger - drug effects | Mice | Staphylococcus aureus - drug effects | Bacillus subtilis - drug effects | Research institutes | Heterocyclic compounds | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
by Appleby, Brian S and Nacopoulos, Dimitrios and Milano, Nicholas and Zhong, Kate and Cummings, Jeffrey L
Dementia and geriatric cognitive disorders, ISSN 1420-8008, 02/2013, Volume 35, Issue 1-2, pp. 1 - 22
Paper | Tauopathies | Pharmacology, clinical | Drug effects | Therapeutics | Amyloid β-peptides | Clinical trials | Amyloid | Drug therapy | Tau proteins | Dementia | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Geriatrics & Gerontology | Science & Technology | Neurology | Biological and medical sciences | Vascular diseases and vascular malformations of the nervous system | Medical sciences | Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases | Hypoglycemic Agents - therapeutic use | Nicotine - therapeutic use | Anti-Asthmatic Agents - therapeutic use | Humans | Alzheimer Disease - drug therapy | Anticonvulsants - therapeutic use | Antineoplastic Agents - therapeutic use | Antihypertensive Agents - therapeutic use | Nicotinic Agonists - therapeutic use | Drug Discovery | Antidepressive Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antipsychotic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Methylene Blue - therapeutic use | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Anti-parkinsonism, hypoglycemic and anti-microbial activities of new poly fused ring heterocyclic candidates
by Al-Harbi, Naif O and Bahashwan, Saleh A and Fayed, Ahmed A and Aboonq, Moutasem S and Amr, Abd El-Galil E
International journal of biological macromolecules, ISSN 0141-8130, 06/2013, Volume 57, pp. 165 - 173
Heterocyclic candidates | Hypoglycemic and anti-microbial activities | Poly ring systems | Anti-parkinsonism | Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Applied | Polymer Science | Science & Technology | Antiparkinson Agents - pharmacology | Anti-Infective Agents - pharmacology | Heterocyclic Compounds, 2-Ring - chemistry | Antiparkinson Agents - chemical synthesis | Hypoglycemic Agents - chemistry | Candida albicans - growth & development | Anti-Infective Agents - chemical synthesis | Heterocyclic Compounds, 2-Ring - pharmacology | Hypoglycemic Agents - pharmacology | Bacteria - growth & development | Animals | Anti-Infective Agents - chemistry | Hypoglycemic Agents - chemical synthesis | Parkinson Disease, Secondary - drug therapy | Antiparkinson Agents - chemistry | Aspergillus fumigatus - growth & development | Mice | Parkinson Disease, Secondary - chemically induced | Heterocyclic Compounds, 2-Ring - chemical synthesis | Drugstores | Parkinson's disease | Pyridine | Antiparkinsonian agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights